Expanding upon his presentation at the recent World EPA Congress, moderator Richard Macaulay and Precision Value & Health have assembled a unique panel of payers from UK, Germany, and Italy, plus experts within Precision to address how innovative reimbursement strategies for cell and gene therapies (C>s) will evolve.
C>s were forecast to pose significant payer challenges due to their transformational, long-term potential patient benefits from single treatments, but having limited clinical data available at launch. However, to date, several high-cost C>s have achieved rapid and broad reimbursement across major payer bodies. Nevertheless, the C> environment is changing with an increasing focus towards larger indications with relatively lower unmet needs alongside the potential for increased competition with multiple C>s launching in the same indication.
Join us for this webinar, which will bring payer representatives from the UK (Andrew Walker), Germany (Frank-Ulrich Fricke), and Italy (Gianluigi Casadei) alongside an industry representative to discuss how payers will respond to this changing C> landscape and how manufacturers can proactively mitigate their strategies, including:
- Will payer concerns over C> increasingly move from uncertainty over long-term benefits to affordability?
- How innovative reimbursement models for C>s have worked to date and where the future direction of travel may take us?
- How will payers respond to having several competing gene or cell therapies in the same indication?
- How divergent will manufacturer approaches need to be across different payers and countries?
The discussion will conclude with a live Q&A.
—